Heron Therapeutics | HRTX - Interest Expense On Debt


Heron Therapeutics reported $600K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
ALKERMES USD 27.55M 1.63M Sep/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amarin USD 3K 5K Dec/2024
ANI Pharmaceuticals USD 3.06M 580K Sep/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
Eisai JPY 1.96B 409M Jun/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.41M 1.57M Sep/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 112.4M 108.78M Sep/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Ultragenyx Pharmaceutical USD 20M 2M Sep/2026
Veracyte USD 2K 1000 Dec/2023
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026